By Mariam Sunny and Jennifer Rigby
May 29 (Reuters) – Global health authorities are racing to identify medical options to help contain an Ebola outbreak in eastern Democratic Republic of Congo, linked to the Bundibugyo strain of the virus.
Unlike for the more common Zaire strain, there are no approved vaccines or treatments for Bundibugyo.
The latest outbreak is suspected to have led to about 906 cases in the Democratic Republic of Congo, including 223 suspected deaths, with the World Health Organization warning that the toll is likely to rise. Bundibugyo ebolavirus, or BDBV, has a fatality rate of up to 40%.
A small number of experimental vaccines and therapies are being assessed, and global health authorities are examining whether any existing Ebola treatments might offer protection — so far supported only by limited animal data.
Most experimental treatments have not yet been tested in humans and would require emergency or compassionate-use authorization before they are deployed in Congo.
The WHO on Thursday recommended prioritizing several experimental drugs, including antibodies, antivirals and vaccines, for the treatment and prevention of BDBV.
Here is what we know of these candidates so far:
VACCINES
1. The WHO said on Thursday a single-dose rVSV Bundibugyo vaccine being developed by the International AIDS Vaccine Initiative is the most promising candidate to prevent BDBV.
The vaccine, rVSVΔG/BDBV-GP, which uses the same technology as Merck's approved vaccine Ervebo for the Zaire strain, has shown survival benefit in non-human primates in a 2023 proof-of-concept study.
The WHO said development of the vaccine would likely take seven to nine months before it is ready for assessment in a clinical trial.
The International AIDS Vaccine Initiative said it is advancing the candidate towards a clinical trial and preparing for manufacturing, including transferring the vaccine virus and processes for Good Manufacturing Practices production.
2. The WHO has recommended prioritizing another vaccine candidate, ChAdOx1 Bundibugyo, being developed by Oxford University and the Serum Institute of India.
The potential vaccine is based on ChAdOx1 technology, which was used in the Oxford/AstraZeneca COVID-19 vaccine, and is being manufactured by the Serum Institute.
The company started production under its "emergency response framework," alongside partners Coalition for Epidemic Preparedness Innovations, or CEPI, and the University of Oxford, as soon as it got word of the outbreak this month, a spokesperson said.
Doses could be ready within two to three months for efficacy assessment through a clinical trial, the WHO said, adding that additional animal studies have yet to be conducted.
The WHO said experts considered a single dose of the vaccine candidate potentially suitable for contacts of Ebola cases, while a two-dose regimen might be used for high-risk but unexposed groups, including healthcare workers and frontline responders.
The Oxford Vaccine Group said it is working to generate pre-clinical data to support the development and testing of the ChAdOx1 BDBV vaccine.
CEPI, which funded some of the early COVID-19 vaccines and aims to have shots available within 100 days of an outbreak, said it is in talks with both candidates about how to speed up development.
ANTIBODY-BASED THERAPIES
1. The WHO has recommended prioritizing privately held Mapp Biopharmaceutical's pan-ebolavirus antibody drug, MBP134 — a combination of two human monoclonal antibodies — for clinical trials among confirmed BDBV cases.
Initially studied for the Sudan ebolavirus strain, the drug was found to be safe and well tolerated in early-stage trials. Development has been backed by the U.S. Biomedical Advanced Research and Development Authority, or BARDA.
BARDA said it is coordinating shipments of the investigational treatment for potential use in high-risk Americans exposed to the virus.
Mapp said MBP134 has shown similar activity against all known ebolaviruses and that it is working with the WHO and other authorities as part of the response to the Congo outbreak.
2. Regeneron Pharmaceuticals' antibody drug candidate, maftivimab, is also being explored as a potential treatment by the WHO. According to the company, it has been shown in a lab to be active against the Bundibugyo Ebolavirus.
Regeneron said it is working to prepare existing supply of maftivimab for use in upcoming clinical trials.
The FDA has approved a combination of maftivimab and two other antibodies, atoltivimab and odesivimab, under the brand name Inmazeb, to treat Zaire Ebolavirus infection in adult and pediatric patients.
The company said it recently donated 500 doses of Inmazeb to the WHO, which could be used if found helpful.
"Supply of Inmazeb is already on the ground in the DRC, should WHO wish to utilize it for immediate treatment or as an additional component of the study," Regeneron said.
3. Human monoclonal antibodies isolated from Bundibugyo survivors have also been explored as potential treatments.
One candidate, BDBV289-N, demonstrated efficacy in a 2018 animal study. The study, conducted by a group of researchers with support from the U.S. National Institutes of Health, showed the antibody gave up to 100% protection in infected monkeys, even when treatment started up to eight days after the infection.
ANTIVIRAL DRUGS
Gilead Sciences' experimental oral antiviral drug obeldesivir is being considered as a potential post-exposure treatment by the WHO to prevent those exposed to Ebola from developing the disease.
Once-daily obeldesivir given for 10 days provided up to 100% protection in monkeys against the Zaire and Sudan Ebola strains when treatment began 24 hours after exposure.
"Obeldesivir is predicted to be active against this particular (Bundibugyo) strain. While not approved for this, we do have preclinical data that shows positive results," a company spokesperson said.
Gilead's antiviral remdesivir has shown activity against the Bundibugyo virus in laboratory studies conducted by researchers at the University of Texas Medical Branch. Some data suggest the drug, given as an intravenous infusion, may have stronger activity against BDBV than against the Zaire Ebola strain.
The WHO has also recommended a combination therapy using a monoclonal antibody and remdesivir for evaluation.
DIAGNOSTIC TESTS
The WHO had indicated that limited testing capacity for the Bundibugyo strain was slowing response to the outbreak. Here are tests that can detect the infection.
1. BioFire Defense, an affiliate of French diagnostic firm bioMérieux, makes an FDA-cleared test – BioFire Global Fever Special Pathogens Panel – that can detect multiple Ebola species, including Bundibugyo.
A company spokesperson said it is increasing production capacity and engaging with public health stakeholders and international contacts to assess potential needs.
2. Germany-based firm Altona Diagnostics' test, called RealStar Filovirus Screen RT-PCR Kit 1.0, is being used to detect the Bundibugyo outbreak in Congo. The firm has ramped up production to support local testing facilities in Congo.
(Reporting by Mariam Sunny in Bengaluru and Jennifer Rigby in Geneva; Editing by Josephine Mason, Rod Nickel and Diti Pujara)
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
